MedElevator
Войти в исследования Annals of surgical oncology · 2026
High Expression of Aurora Kinase A (AURKA) is Associated with Aggressive Tumor Biology and Therapeutic Response in ER+/HER2- Breast Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elsaedy Eslam A, AlRammah Tamrah, Kawashima Kei, Ebos John M L, Katsuta Eriko, Opyrchal Mateusz, Narui Kazutaka, Yamada Akimitsu, Takabe Kazuaki
Аннотация
BACKGROUND: Aurora kinase A (AURKA) is a serine/threonine kinase that regulates mitotic entry, spindle assembly, and chromosomal segregation. AURKA overexpression has been linked to multiple malignancies. The biological and clinical significance of AURKA expression within estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer has yet to be fully elucidated.
METHODS: A total of 8896 patients were analyzed across bulk transcriptomic datasets. Single-cell RNA sequencing datasets were also analyzed. ER+/HER2- tumors were divided into AURKA-high or -low groups according to the median AURKA expression within each cohort.
RESULTS: AURKA expression was associated with Nottingham histological grade and Ki-67 expression (p < 0.001) and enrichment of cell cycle-related pathways across The Cancer Genome Atlas, Molecular Taxonomy of Breast Cancer International Consortium, and Sweden Cancerome Analysis Network-Breast datasets (all false discovery rate <0.01; normalized enrichment score >2). AURKA expression was associated with genomic instability, increased mutational burden and enhanced DNA repair-related genes (all p < 0.001) and with increased infiltration of type 1 and 2 T-helper cells, M1-like macrophages, and total macrophages (all p < 0.001). Conversely, AURKA-low tumors were enriched for epithelial mesenchymal transition, myogenesis, coagulation, angiogenesis, and transforming growth factor-β signaling pathways (most false discovery rate <0.01) and higher cancer stem cells score (all p < 0.001). Clinically, higher AURKA expression was associated with pathological complete response after neoadjuvant chemotherapy in three of nine ER+/HER2- cohorts and with worse survival outcomes. AURKA expression also decreased after neoadjuvant chemotherapy in all three paired cohorts analyzed, regardless of subtype.
CONCLUSION: High AURKA expression was associated with a highly proliferative, immune-engaged tumor phenotype and with worse survival despite better therapeutic response in ER+/HER2- breast cancer.
METHODS: A total of 8896 patients were analyzed across bulk transcriptomic datasets. Single-cell RNA sequencing datasets were also analyzed. ER+/HER2- tumors were divided into AURKA-high or -low groups according to the median AURKA expression within each cohort.
RESULTS: AURKA expression was associated with Nottingham histological grade and Ki-67 expression (p < 0.001) and enrichment of cell cycle-related pathways across The Cancer Genome Atlas, Molecular Taxonomy of Breast Cancer International Consortium, and Sweden Cancerome Analysis Network-Breast datasets (all false discovery rate <0.01; normalized enrichment score >2). AURKA expression was associated with genomic instability, increased mutational burden and enhanced DNA repair-related genes (all p < 0.001) and with increased infiltration of type 1 and 2 T-helper cells, M1-like macrophages, and total macrophages (all p < 0.001). Conversely, AURKA-low tumors were enriched for epithelial mesenchymal transition, myogenesis, coagulation, angiogenesis, and transforming growth factor-β signaling pathways (most false discovery rate <0.01) and higher cancer stem cells score (all p < 0.001). Clinically, higher AURKA expression was associated with pathological complete response after neoadjuvant chemotherapy in three of nine ER+/HER2- cohorts and with worse survival outcomes. AURKA expression also decreased after neoadjuvant chemotherapy in all three paired cohorts analyzed, regardless of subtype.
CONCLUSION: High AURKA expression was associated with a highly proliferative, immune-engaged tumor phenotype and with worse survival despite better therapeutic response in ER+/HER2- breast cancer.